
**PDVAC virtual session 3: Full Vaccine Value Assessment for Shigella Vaccines
18 May 2020**

PDVAC COMMITTEE MEMBERS

Isabelle Bekerédjian-Ding (for) Klaus Cichutek
Paul-Ehrlich-Institute (PEI)
Langen, Germany

klaus.cichutek@pei.de
Isabelle.Bekerédjian-Ding@pei.de

Sinead Delany-Moretlwe
University of Witwatersrand (Wits)
Johannesburg, South Africa

sdelany@wrhi.ac.za

Bernard Fritzell
Independent
Bordeaux, France

bernardfritzell@hotmail.fr

Barney Graham
NIAID, Vaccine Research Center
Bethesda, USA

bgraham@mail.nih.gov

Gagandeep Kang
Translational Health Science and Technology
Institute (THSTI)
Faridabad, India

gkang@thsti.res.in

Ruth Karron
Johns Hopkins Bloomberg School of Public Health
(JHSPH)
Baltimore, USA

rkarron@jhsphe.edu

Jerome Kim
International Vaccine Institute (IVI)
Seoul, Korea

Jerome.Kim@ivi.int

David Kaslow (CHAIR)
PATH
Seattle, USA

dkaslow@path.org

Claudio Lanata
Instituto de Investigación Nutricional
Lima, Peru

clanata@iin.sld.pe

Shabir Madhi
Witwatersrand University
Johannesburg, South Africa

madhis@rmpru.co.za

Beno Y. Nyam

National Agency for Food and Drug Administration and Control
Lagos, Nigeria

beno.y@nafdac.gov.ng

Mark Papania

Centers for Disease Control and Prevention
Atlanta, USA

myp7@cdc.gov

Yiming Shao

Chinese Center for Disease Control and Prevention (CDC)
Beijing, China

yshao@bjmu.edu.cn

Peter Smith

London School of Hygiene and Tropical Medicine (LSHTM)
London, UK

Peter.Smith@lshtm.ac.uk

Marian W. Wentworth

Management Sciences for Health (MSH)
Medford, USA

mwentworth@msh.org

NON- MEMBER PARTICIPANTS**Alejandro Cravioto**

University of Mexico
Puerto Vallarta, Mexico

dracravioto@hotmail.com

Mark Jit

LSHTM
London, UK

Mark.Jit@lshtm.ac.uk

Farzana Muhib

PATH
Washington DC, USA

fmuhib@path.org

Karen Kotloff

University of Maryland
Baltimore, USA

Kkotloff@som.umaryland.edu

Patty Pavlinac

University of Washington
Seattle, USA

ppav@uw.edu

James Platts-Mills

University of Virginia
Charlottesville, USA

P5T@hscmail.mcc.virginia.edu

Chad Porter

Naval Medical Research Center
Maryland, USA

chad.k.porter2.civ@mail.mil

OBSERVERS

Louis Bourgeois

PATH

Seattle, USA

lbourgeois@path.org

Caroline Deal

NIAID NIH

Bethesda, USA

cdeal@niaid.nih.gov

Jeroen Geurtsen

Head Molecular Bacteriology & Bacterial Epidemiology

Janssen

Netherlands

jgeurtse@its.inj.com

William Hausdorff

PATH

Seattle, USA

whausdorff@path.org

Jens Kieckbusch

Wellcome

London, UK

J.Kieckbusch@wellcome.ac.uk;

Cal MacLennan

Bill & Melinda Gates Foundation

London, UK

Calman.MacLennan@gatesfoundation.org

Sophie Mathewson

GAVI

Geneva, Switzerland

smathewson@gavi.org

Francesca Micoli

GSK

Milan, Italy

francesca.x.micoli@gsk.com

Sally Nichols

Wellcome Trust

London, UK

S.Nichols@wellcome.ac.uk

Deepali. Patel

GAVI, the Vaccine Alliance

Geneva, Switzerland

dpatel@gavi.org

Suzanne Scheele

PATH

San Francisco, USA

sscheele@path.org

Duncan Steel

Bill & Melinda Gates Foundation

Seattle, USA

Duncan.Steele@gatesfoundation.org

Martin Friede, Unit Head, Vaccine Product & Delivery Research, IVB

Birgitte Giersing, Team Lead (a.i.), Vaccine Prioritization and Platforms, Vaccine Product & Delivery Research, IVB

Mateusz Hasso-Agopsowicz, Consultant, Vaccine Product & Delivery Research, IVB

Raymond Hutubessy, Team Lead, Value of Vaccines, Immunization Analysis and Insights Unit, IVB

Ibrahim Khalil, Consultant, Vaccine Product & Delivery Research, IVB

Philipp Lambach, Medical Officer, Vaccine Product & Delivery Research, IVB

So Yoon Sim, Technical Officer, Value of Vaccines, Immunization Analysis & Insights, IVB

Erin Sparrow, Technical Officer, Vaccine Prioritization and Platforms, Vaccine Product & Delivery Research, IVB

Johan Vekemans, Team Lead Vaccine Development (a.i.), Vaccine Product & Delivery Research, IVB
